NCT06963827: An ongoing trial by Takeda
This trial is ongoing. It must report results 4 years from now.
Full data
| Full entry on ClinicalTrials.gov | NCT06963827 |
|---|---|
| Title | A Phase 3 Multicenter, Randomized, Double-Blind, Placebo Controlled Trial to Evaluate Efficacy and Safety of Mezagitamab (TAK-079) in Study Participants With Primary IgA Nephropathy in Combination With Stable Background Therapy |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | July 15, 2025 |
| Completion date | Sept. 7, 2028 |
| Required reporting date | Sept. 7, 2029, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Aug. 26, 2025 |
| Days late | None |